Ethic Inc’s Avalo Therapeutics AVTX Stock Holding History

Ethic Inc’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-7	Closed	-$34K	–	747
2021 Q4	$34K	Buy	+7	New	+$42K	﹤0.01%	657

Other funds holding AVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Ethic Inc's AVTX Position: Q1 2022 in Review

Ethic Inc sold out of Avalo Therapeutics (AVTX) in Q1 2022, closing a stake of 7 shares — an estimated $34K sold.

Ethic Inc first reported a position in AVTX in Q4 2021 and held it in 1 quarter. The position peaked at $34K in Q4 2021. 65 funds tracked by Wall St. Rank hold AVTX as of Q1 2022.

Ethic Inc reported no remaining Avalo Therapeutics position as of Q1 2022 after selling out during the quarter.
Ethic Inc sold 7 Avalo Therapeutics shares in Q1 2022, an estimated $34K.
Ethic Inc first reported a position in Avalo Therapeutics in Q4 2021 and held it in 1 quarter.
Ethic Inc's Avalo Therapeutics position peaked at $34K in Q4 2021.
65 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2022.

Based on Ethic Inc's 13F filing for Q1 2022, filed 16 May 2022.